anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Unresectable, isolated lymph node recurrence after radiotherapy is rare but a candidate for re-irradiation. However, severe toxicity is anticipated. Therefore, this study aimed to explore the efficacy and toxicity of re-irradiation in isolated lymph node recurrence of head and neck lesions. We analyzed 46 patients who received re-irradiation for lymph node recurrence without local progression. The primary tumor sites included the oral cavity in 17 patients, the hypopharynx in 12, the oropharynx in seven, the larynx in three, the nasopharynx in two, and other sites. During a median follow-up time of 10 months, the median survival time was 10.6 months, and the 1-year overall survival rate was 45.5%. The 1-year local control and progression-free survival rates were 49.8% and 39.3%, respectively. According to univariate analysis, age (≥ 65 years), the interval between treatment (≥ 12 months), rN category (rN1), and gross tumor volume (GTV < 25 cm3) were predisposing factors for better survival. In the multivariate analysis, the rN category and interval were identified as statistically significant predictors. Late toxicity grade ≥ 3 occurred in four patients (8.6%). These were all Grade 5 carotid blowout syndrome, which associated with tumor invasion of the carotid artery and/ or high doses administration for the carotid artery. Small-volume rN1 tumor that recur after a longer interval is a feasible candidate for re-irradiation. However, strict patient selection and meticulous care for the carotid are required.
FIELD: veterinary biotechnology. SUBSTANCE: serum contains antibodies to Fusobacterium necrophorum in a titer being not lower than 1:128 in reaction of agglutination (RA). It is obtained by hyperimmunization of producer bullocks with inactivated formalin leucocydine-exotoxin. The latter is a highly purified protein at 18-20 kDa molecular weight isolated from a production strain Fusobacterium necrophorum "0- 1" VIEV. Hyperimmune serum provides the development of tense passive immunity against necrobacteriosis in cattle and reindeers in case of single injection for about 14 d, not less Therapy efficiency corresponds to 90%. EFFECT: higher efficiency. 2 ex, 1 tbl
Diastolic heart failure without left ventricular systolic dysfunction comprises 30% to 50% of heart failure in clinical practice, and hypertensive heart disease is a major cause of this type of heart failure. The complication of myocardial fibrosis should be avoided in hypertensive heart disease, because increasing ventricular stiffness caused by myocardial fibrosis leads to the development of diastolic dysfunction of the heart. Diastolic dysfunction in patients with prolonged hypertension is often associated with myocardial fibrosis in addition to muscular hypertrophy as a final feature of hypertensive heart disease. The high risk of developing maladaptive cardiac remodeling during hypertension, and failure of pharmacological treatments to limit or even reverse this progressive stiffening of the myocardium, has led to the study of effects of Pycnogenol, a bioflavonoid-rich pine bark extract, with pleiotropic actions on cardiovascular system. Pycnogenol prevents adverse hypertension-induced myocardial remodeling in mice, through modulation of gene expression and activity of enzyme matrix metalloproteinases and their tissue inhibitors, affecting myocardial collagen degradation rate. Despite the mounting evidence suggesting the anti-remodeling effect of Pycnogenol in animal models, the clinical efficacy of Pycnogenol in hypertension-induced diastolic dysfunction is unreported. This leads to our central hypothesis that Pycnogenol reverses the hypertension-induced cardiac fibrosis and diastolic dysfunction in hypertensive patients. Therefore in this clinical investigation, we will investigate the effects of Pycnogenol in modifying hypertension-induced cardiac fibrosis (by measuring the serum markers of myocardial fibrosis and collagen turnover) and diastolic dysfunction (by transthoracic echocardiogram). We expect to improve diastolic function and ameliorate myocardial fibrosis with the nutritional supplement Pycnogenol, by modulation of MMPs and TIMPs enzyme activities.
Stool and blood samples etc. were taken from a cohort of patients with ulcerative colitis treated with Vedolizum at the Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine as well as from a cohort of normal volunteers. Stool and blood samples from UC patients were analyzed at baseline and at 14, 30, and 52 weeks after starting treatment. Analysis of changes in gut microbial composition and abundance, gut and serum metabolome characteristics during 52 weeks of treatment in patients with UC. A model for predicting the efficacy of vedolizumab treatment by baseline gut microbial composition and abundance, and gut and serum metabolomic characteristics in patients with ulcerative colitis was developed in conjunction with clinical information from patients in the cohort. Based on the model developed, clinical and gut microbial composition and abundance, gut and serum metabolomics data from other UC patients published in public databases were combined to confirm the results already found using the UC cohort at our center.
The V.A.C.Ulta™ Negative Pressure Wound Therapy System is a 510(k) -cleared, Class II device (K100657) with the following indication for use: "the V.A.C.Ulta™ Negative Pressure Wound Therapy System is an integrated wound management system that provides Negative Pressure Wound Therapy with an instillation option. Negative Pressure Wound Therapy in the absence of instillation is intended to create an environment that promotes wound healing by secondary or tertiary (delayed primary) intention by preparing the wound bed for closure, reducing edema, promoting granulation tissue formation and perfusion, and by removing exudates and infectious material. The instillation option is indicated for patients who would benefit from vacuum assisted drainage and controlled delivery of topical wound treatment solutions and suspensions over the wound bed. The V.A.C.Ulta™ Negative Pressure Wound Therapy System, with and without instillation, is indicated for patients with chronic, acute, traumatic, sub-acute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure and venous insufficiency), flaps and grafts". The V.A.C. Ulta™ Therapy Unit is for use with only V.A.C.® Dressings (V.A.C.® GranuFoam™, V.A.C. GranuFoam Silver®, V.A.C. WhiteFoam,® V.A.C. VeraFlo™ Dressing Systems) and disposables. The V.A.C. VeraFlo™ Dressing System is intended for use with V.A.C. VeraFlo™ Therapy as provided by the V.A.C.Ulta™ Therapy Unit. The V.A.C. VeraFlo™ Dressing was cleared under the V.A.C Ulta™ Negative Pressure Wound Therapy System 510(k) (K100657). It is recommended for use with open wounds, including wounds with shallow undermining or tunnel areas where the distal aspect is visible.

Prontosan® Wound Irrigation Solution is a clear, odorless, colorless solution consisting of polyhexamethylene biguanide (PHMB), betaine, sodium hydroxide and purified water. PHMB, also known as Polyhexanide, is a polymer biguanide. PHMB is a cationic preservative which inhibits the growth of microorganisms within the product. Betaine is a zwitterionic (both, negatively and positively charged) surfactant. Prontosan® is a FDA 510(k) cleared device intended for cleaning wounds and for moistening and lubricating absorbent wound dressings for ulcers, burns, post surgical wounds, and abrasions.

The objective to this study is to determine the effectiveness of V.A.C.Veraflo negative pressure wound therapy with Prontosan instillation, when compared to historical controls of V.A.C Therapy without instillation in the management of wounds. We will measure any difference in length of hospital stay, number of days until final surgical procedure, and the number of trips to the or for additional debridement. Patients will be considered infection free when clinical signs of infection are absent and lab values become normal.
PURPOSE:To produce a substance having antiallergic activity, by using the fruit body or artificially cultured mycelia of Sarcodon aspratus as the starting raw material. CONSTITUTION:The fruit body or artificially culture mycelia of Sarcodon aspratus is treated with an aqueous solution of a lower alcohol such as methanol to remove low-molecular compounds (e.g. monosaccharide, fat, etc.), and the residue is extracted with hot water. The extract is added with acetone or a lower alcohol, and the resultant precipitate is collected. A fraction having a nolecular weight of >=7,000 is separated by the dialysis of the extract with a cellulose membrane immediately before or after the precipitation process. An antiallergic substance coustin can be produced by purifying the extract by ion exchange immediately before or after the above processes, and if necessary, purifying the product by gel-filtration. It is an excellent antiallergic agent effective at a low dose and free from side effects.
Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
Three 6-month, multicenter, randomized, double-blind, placebo-controlled clinical studies of similar design were conducted in patients with CKD on dialysis. A total of 665 patients were randomized to Sensipar and 471 patients to placebo. The mean age of the patients was 54 years, 62% were male, and 52% were Caucasian. The average baseline iPTH level by the Nichols IRMA was 712 pg/mL, with 26% of the patients having a baseline iPTH level > 800 pg/mL. The mean baseline Ca x P product was 61 mg2/dL2. The average duration of dialysis prior to study enrollment was 67 months. Ninety-six percent of patients were on hemodialysis and 4% on peritoneal dialysis. At study entry, 66% of the patients were receiving vitamin D sterols and 93% were receiving phosphate binders. Sensipar (or placebo) was initiated at a dose of 30 mg once daily and titrated every 3 or 4 weeks to a maximum dose of 180 mg once daily to achieve an iPTH of ≤ 250 pg/mL. The dose was not increased if a patient had any of the following: iPTH ≤ 200 pg/mL, serum calcium < 7.8 mg/dL, or any symptoms of hypocalcemia. If a patient experienced symptoms of hypocalcemia or had a serum calcium < 8.4 mg/dL, calcium supplements and/or calcium-based phosphate binders could be increased. If these measures were insufficient, the vitamin D dose could be increased. Approximately 70% of patients in the Sensipar arm and 80% of the patients in the placebo arm completed the 6-month studies. In the primary efficacy analysis, 40% of the patients on Sensipar and 5% of placebo-treated patients achieved an iPTH ≤ 250 pg/mL (p < 0.001) (Table 7, Figure 1). These studies showed that Sensipar reduced iPTH while lowering Ca x P, calcium, and phosphorus levels (Table 7, Figure 2). The median dose of Sensipar at the completion of the studies was 90 mg. Patients with milder disease typically required lower doses.

Similar results were observed when either the iPTH or biointact PTH (biPTH) assay was used to measure PTH levels in CKD patients on dialysis; treatment with cinacalcet did not alter the relationship between iPTH and biPTH. 

Reductions in iPTH and Ca x P were maintained for up to 12 months of treatment.

Sensipar decreased iPTH and Ca x P levels regardless of disease severity (i.e., baseline iPTH value), duration of dialysis, and whether or not vitamin D sterols were administered. Approximately 60% of patients with mild (iPTH ≥ 300 to ≤ 500 pg/mL), 41% with moderate (iPTH > 500 to 800 pg/mL), and 11% with severe (iPTH > 800 pg/mL) secondary HPT achieved a mean iPTH value of ≤ 250 pg/mL. Plasma iPTH levels were measured using the Nichols IRMA.
The participant will receive 2 Respiratory Sensors and 1 gateway with wireless compatibility and a welcome packet with instructions for use, a reminder description of the study purpose and procedures, and research staff contact information. Research staff will contact participants to ensure appropriate setup of the Respiratory Sensor and training on proper use. Research staff will ask the subject to place the Respiratory Sensor on the top left-side of the chest. The Respiratory Sensor continuously collects and monitors respiratory data. The participant will be instructed to change each Respiratory Sensor after 24-48 hours. Subjects will be asked to charge each Respiratory Sensor once it is removed. Subjects will exit the study upon completion of the 90-day follow-up.
The past 30 years have witnessed significant increases in the prevalence of type 2 diabetes mellitus (T2DM) in China. China now is estimated 114 million people with diabetes, T2DM accounts for more than 90% of the overall population with diabetes in China. A large proportion of diabetes is undiagnosed in China: in the 2007-2008 national survey among adult population over 20 years, patient with newly diagnosed diabetes accounted for 60% of total diabetes population. In the Healthy China 2030 Plan, approved by the State Council and the Party's Central Committee, diabetes, along with cancer, hypertension, and cardiovascular diseases, are listed as the four major non-communicable diseases (NCDs) for which the goal is to "control the prevalence and reduce the probability of early death". Metformin hydrochloride is the primary biguanide medication currently used in China's medical practice. Sodium-glucose cotransporter 2 (SGLT2) inhibitors used to be considered as second-line treatment after Metformin in patients with T2DM. But according to the American Diabetes Association (ADA) 2023 Standards of Medical Care in Diabetes, SGLT2 inhibitors are now recommended to be started at the time of diagnosis as the first-line medications, for high-risk individuals with atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) or chronic kidney disease (CKD). Compared with stepwise therapy, early combination therapy may provide earlier and greater reductions in HbA1c and thus achievement of glycemic target. In addition, SGLT2 inhibitors provide cardiorenal protection both in patients with and without T2DM, that goes beyond glycemic control, hence the recommendation by guidelines to implement SGLT2 inhibitors. But early combination therapy is not fully implemented into clinical practice in China. International and CDS guidelines recommends encourage using fixed-dose combination (FDC) to have better adherence, which is associated with lower HbA1c, lower cost and less need for acute care. But in practice, FDC is not popular in China because of many reasons. One of the main arguments is that physicians think FDC lacks flexibility. Compelling evidence has shown that the co-administration of Dapagliflozin and Metformin extended-release (XR) tablets is superior to either of the monotherapy efficacy (Dapagliflozin or Metformin XR). Xigduo XR combines those two anti-hyperglycemic medicinal products with different and complementary mechanisms of action to improve glycemic control in patients with T2DM. Bioequivalence was demonstrated between FDC regimen and coadministered Dapagliflozin and Metformin HCl XR tablets. This dosage of Dapagliflozin 10 mg/Metformin hydrochloride XR 1000 mg FDC (Xigduo XR) has no clinical evidence except that bioequivalence study in China, and there are no combination therapy data available either for Chinese people. (Metformin XR usual dose is 1500-2000mg/d). Moreover, there is no head-to-head study comparing Dapa/Met FDC and co-administration therapies to the extra benefits of FDC.
The present invention provides a wine with the functions of immunity improvement, body strengthening and happiness promotion and a preparation method thereof. The wine with the functions of immunity improvement, body strengthening and happiness promotion is prepared from acanthopanax, fructus lycii, cherokee rose fruit, mulberry, dogwood fruit pulp, Chinese yam, sea horse, orange peel, flos caryophyllata, sorghum, glutinous rice, wheat, wheat bran, corn flour and rice chaff through the following steps of cultivation of bloodthirsty bacterium Saccharomyces Cerevisiae CGMCC NO. 0775, strain enlargement cultivation, leaven preparation, Xiangpei preparation, spirit preparation, glutinous rice medicinal wine natural starter preparation and finished product wine preparation. A strain 0775 is a good strain which has the advantages of acid resistance, high temperature resistance, high wine yield and high ester yield, and has strong bloodthirsty activity. The strain 0775 can kill affinity congener wild bacteria so as to make fermentation mash not polluted and ensure pure strain fermentation, and is preserved in the Common microorganism Center of China Committee for Culture Collection of Microorganisms. The wine of the present invention has the multiple functions of nourishing the kidney, strengthening yang, strengthening the body, resisting ageing, preventing senescence, allaying tiredness, enhancing human body immunizing power, etc.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to therapy and endocrinology, and can be used in treating patients suffering type 2 diabetes mellitus. That is ensured by a continuous exenatide delivery by implanting into a patient into an osmotic delivery device comprising an impermeable container, a semi-permeable membrane, an osmotic mechanism integrated into the container and adjoining the semi-permeable membrane, a piston adjoining the above osmotic mechanism; the above piston forms a movable seal with an inner surface of the container and divides the container into a first chamber comprising the osmotic mechanism, and a second chamber comprising a suspension formulation, and a diffusion adjustor. The suspension formulation contains a particle formulation containing exenatide particles having a diameter of less than 10 to 30 mcm. The delivery formulation contains a solvent specified in a group consisting of benzyl benzoate, lauryl lactate and lauryl alcohol, and polyvinylpyrrolidone polymer. The delivery formulation has a viscosity of approximately 10,000 poise to approximately 20,000 poise at 37°C. The continuous exenatide delivery in the therapeutic concentration is ensured for 5 days or less. The continuous exenatide delivery from the osmotic delivery device in a dose of exenaide of 10 mcg/day, 20 mcg/day, 30 mcg/day, 40 mcg/day, 60 mcg/day, and 80 mcg/day can be effected through at least three months.EFFECT: method enables the effective treatment of the given pathology by the fast achievement and long maintenance of the exenatide concentration to be completed rapidly with no constant injections or oral administration.15 cl, 20 tbl, 21 dwg, 4 ex
Oxidising residues are removed from protein fibres, e.g. woll and hair, after treatment with hydrogen peroxide, carbamide peroxide, sodium perborate, potassium persulphate, sodium percarbonate or sodium perphosphate by treating them with a chlorite-free reagent containing an a -carbonyl carboxylic acid having the formula R-CO-COOH in which R is an alkyl radical or a hydrogen atom or a salt thereof, e.g. pyruvic or glyosylic acid. The treating composition may have an acid or alkaline pH value and may be an aqueous, alcoholic or water-alcohol composition.  The composition may also contain a perfume, amonia, tartaric acid, lauryl pyridinium chloride, sodium sulphate or polyvinyl pyrrolidone.  The process is applicable to the treatment of hair waved by treatment with thioglycollate solutions and hydrogen peroxide to the treatment of hair dyed with oxidation dyestuffs, to the treatment of hair after bleaching prior to dyeing, to the setting of hair and to the after treatment of bleached wool.ALSO:A composition suitable for use in the treatment of hair to remove oxidising residues therefrom comprises an a -carbonyl carboxylic acid of the formula R,CO,COOH in which R is an alkyl radical or a hydrogen atom or a salt thereof, e.g. pyruvic or glyoxylic acid, and a perfume oil or dry perfume.  The composition may be applied to the hair as an aqueous, alcoholic or water-alcohol composition after bleaching, waving or dyeing with oxidation dyestuffs involving the use of hydrogen peroxide, carbamide peroxide, sodium perborate, potassium persulphate, sodium percarbonate or sodium perphosphate.  The composition may be applied in the form of a setting agent comprising polyvinyl pyrrolidone, the sodium salt of pyruvic acid, tartaric acid, isopropyl alcohol, perfume oil and water.
The precise mechanism(s) by which levetiracetamexerts its antiepileptic effect is unknown. The antiepileptic activity oflevetiracetam was assessed in a number of animal models of epileptic seizures.Levetiracetam did not inhibit single seizures induced by maximal stimulationwith electrical current or different chemoconvulsants and showed only minimalactivity in submaximal stimulation and in threshold tests. Protection was observed,however, against secondarily generalized activity from focal seizures inducedby pilocarpine and kainic acid, two chemoconvulsants that induce seizures thatmimic some features of human complex partial seizures with secondarygeneralization. Levetiracetam also displayed inhibitory properties in thekindling model in rats, another model of human complex partial seizures, bothduring kindling development and in the fully kindled state. The predictivevalue of these animal models for specific types of human epilepsy is uncertain.

In vitroand in vivo recordings ofepileptiform activity from the hippocampus have shown that levetiracetaminhibits burst firing without affecting normal neuronal excitability,suggesting that levetiracetam may selectively prevent hypersynchronization ofepileptiform burst firing and propagation of seizure activity.

Levetiracetam at concentrations of up to 10 µMdid not demonstrate binding affinity for a variety of known receptors, such asthose associated with benzodiazepines, GABA (gamma-aminobutyric acid), glycine,NMDA (N-methyl-D-aspartate), re-uptake sites, and second messenger systems.Furthermore, in vitro studies have failed to find an effect of levetiracetam onneuronal voltage-gated sodium or T-type calcium currents and levetiracetam doesnot appear to directly facilitate GABAergic neurotransmission. However, in vitro studies have demonstrated thatlevetiracetam opposes the activity of negative modulators of GABA- andglycine-gated currents and partially inhibits N-type calcium currents inneuronal cells.

A saturable and stereoselective neuronal bindingsite in rat brain tissue has been described for levetiracetam. Experimentaldata indicate that this binding site is the synaptic vesicle protein SV2A,thought to be involved in the regulation of vesicle exocytosis. Although themolecular significance of levetiracetam binding to synaptic vesicle proteinSV2A is not understood, levetiracetam and related analogs showed a rank orderof affinity for SV2A which correlated with the potency of their antiseizureactivity in audiogenic seizure-prone mice. These findings suggest that theinteraction of levetiracetam with the SV2A protein may contribute to theantiepileptic mechanism of action of the drug.